Home           |           About Us           |           Register Free           |           Events and Conferences           |           Contact Us
 
News
Companies
Education
Publications
Links
Parks
 
 
 
 
 
 
 
Top Stories
 
Looking beyond the drug receptor for clues to drug effectiveness
Durham, N.C.
26 August 2008

Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.

Scientists have known that all antipsychotic drugs target the D2 receptor inside cells. New tests developed at Duke reveal that the biochemical pathways linked to this receptor - the pathways along which the drugs deliver their therapeutic effects - may function differently than previously understood.
---------------------------------------------------------------------------------------------------------
Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
Vancouver, BC
21 August 2008

Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908. The Company received FDA and Health Canada approval for the clinical trial earlier this year.
---------------------------------------------------------------------------------------------------------
HSC-Institute of Biosciences and Technology researchers learn about role of mutated DNA repeats in diseases like cancer
Houston
21 August 2008

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology in Houston have uncovered new information about the role of certain mutated segments of DNA in forming diseases like cancer. This finding could someday lead to therapies targeting the mutated DNA segments.
---------------------------------------------------------------------------------------------------------
Enobia Pharma initiates clinical testing of Enzyme Replacement Therapy to treat hypophosphatasia
Montreal
20 August 2008

Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.
---------------------------------------------------------------------------------------------------------
BIO Supports EPA Denial of Renewable Fuel Standard
Washington, D.C.
07 August 2008

The Renewable Fuel Standard (RFS) provides crucial support and incentives for companies to invest in new biorefineries to bring advanced biofuels to the pump. Biotechnology Industry Organization (BIO) President & CEO Jim Greenwood released the following statement expressing the industry’s support for the U.S. Environmental Protection Agency’s decision not to grant Texas Gov. Rick Perry’s petition to cut the RFS.
---------------------------------------------------------------------------------------------------------
More Biotech News
-----------------------------------------------------------
« Fingerprints Provide Clues To More Than Just Identity
« FDA Grants Conditional Approval to Interventional Spine’s PercuDyn™ System IDE Application
« Vaccine Containing Tumor Antigen Check Colon Cancer Spread in Mice
« Jefferson Scientists Find Blocking Signaling Protein Prevents Prostate Cancer Spread
« CLC bio releases Next Generation Sequencing data analysis solution
« AstraZeneca Submits sNDA With U.S. FDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indicatio
« Genasense(R) Chemotherapy Show High Response Rate in Patients with Stage 4 Melanoma
« Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
« Genetic testing for everyone
« Avecia Biotechnology Chooses Pilgrim Software’s SmartSolve Solution
« Eastern Biotech To Offer Newborn Screening in Middle East
« Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
« DuBiotech Announces Gulf Anti-doping and Monitoring Enterprise (GAME)
« AED289 Million DuBiotech Laboratory Complex to be Operational in September 2008
« DuBiotech Unveils BioTiqania Advanced Training Institute
-----------------------------------------------------------
NEWS ARCHIVES
-----------------------------------------------------------
 
 
 
 
 
 
 
 
 
Other Arab Online Media Websites
Education ME | Arab Medical Tourist | Biotech Arabia | The Islamic Banker | Earth Arabia |
The Gold Souq | Arab Franchise | Freezones Arabia |
Charity Arabia | Dentalcare Traveler |
Wellness Arabia
| Stemcell arabia |
Arab billionaires | Arabnanotech | Aviation Arabia|
gg
 
© 2007 Arab Online Media All Rights Reserved Privacy Policy | Advertising Policy| Disclaimer
Last update: